1 FDA/CDRH PUBLIC MEETING; Blood Glucose Meters FDA/CDRH PUBLIC MEETING; Blood Glucose Meters FDA Perspective: Regulatory Challenges for Safe use of Blood.

Slides:



Advertisements
Similar presentations
FDA QS reg/CLIA Comparison: Overview
Advertisements

POC Leadership Forum Update on the Regulations CLIA, CAP, JCAHO and COLA Ronald H. Laessig, Ph.D. University of Wisconsin Madison, Wisconsin
Point of Care Testing BOPCC May 31, 2011 Beatrice OKeefe, Chief Laboratory Field Services California Department of Public Health.
Bay Area POCC Spring Meeting Stanford University Medical Center
1 Testing in the Open Market Testing in the Open Market AAAS Colloquium on Personalized Medicine: Planning for the Future June 2, 2009 Courtney C. Harper,
Infection Control Program
FDA Perspective: FDA Evaluation of Point of Care Blood Glucose Meters
Comparison GHTF/SG5/N5:2012 vs. MEDDEV 2.7/3:2010
Sue Woodward Chair Patent Liaison Group RCS Eng 12 October 2011.
P OINT OF CARE TESTING Lecture 6. D EFINITION Medical testing at or near the site of patient care. It is a mode of analysis which is performed at the.
The Joint Commission Chapter update: Waived Testing
Glucose, Whole Blood Accu-Chek Inform II®
Principles of FDA Regulation for In Vitro Diagnostic Tests for Home Use Carol C. Benson OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel.
CLIA Waived Testing for Physician Office Labs Doris Thompson, Ph.D., MT (ASCP) AK State Public Health Laboratories State CLIA Program Francisca Lehr, M.S.,
MLAB 2401: C LINICAL C HEMISTRY K ERI B ROPHY -M ARTINEZ Point of Care Testing 1.
IVD and Point of care testing
Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.
1 Quality System Considerations for Over-The-Counter HIV Testing Devery Howerton, Ph.D. Chief, Laboratory Practice Evaluation and Genomics Branch, Division.
Always practice proper hand hygiene and change gloves between each person. Label each individual piece of equipment with the resident’s name to prevent.
Infection Prevention in Point of Care Testing. Point of Care Testing (POCT) Diagnostic testing at or near the site of patient care Uses portable handheld.
1 FDA/CDRH PUBLIC MEETING: Blood Glucose Meters FDA/CDRH PUBLIC MEETING: Blood Glucose Meters FDA Perspective - Public Health Notification: Potentially.
25 TAC Quality Assurance in a licensed ASC
CDRH Review Practice for Over-the-Counter in Vitro Diagnostic Tests
Quality Control Barbara Weberman MT(ASCP) Oakland County Health Division Laboratory Supervisor.
INPATIENT DIABETES GUIDE Ananda Nimalasuriya M.D..
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
William B Munier, MD, MBA, Director Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality AHRQ Annual Conference.
Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Patient Safety Initiatives Kelly Cronin Director, Patient Safety and Outcomes Research Office of Policy and Planning Office of the Commissioner FDA.
Serious adverse events following falsely high glucose measurements resulting from administration of an IGIV product containing maltose L. Ross Pierce,
2012 Quality and Patient Safety Performance Results Annual Report The Quality Committee of the Board Confidential & Privileged Peer Review Materials; Pages.
Choosing a Blood Glucose Meter Why, When, How, and What Presented by Ron Kammer RN CDE.
Accu-Chek Inform II Blood Glucose Monitoring System.
NORTH AMERICAN SAFETY CHECKLIST – SB 158. Rhonda Anderson, RHIA President Anderson Health Information Systems, Inc. Presented By:
What Makes a Good Medical Device Adverse Event Report?
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
1 Accreditation and Certification: Definition  Certification: Procedures by which a third party gives written assurance that a product, process or service.
MassMEDIC Risk Management: Legal and Liability Issues with Home Healthcare Products Raymond C. Zemlin Goodwin Procter LLP (March 9, 2006) ©2006. Goodwin.
© Copyright 2009 by the American Association for Clinical Chemistry Glucose Meter Performance Criteria for Tight Glycemic Control Estimated by Simulation.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
PROPRIETARY NAME EVALUATION AT FDA Jerry Phillips, RPh Associate Director for Medication Error Prevention Office of Drug Safety December 4, 2003.
Biomedical Research.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
CDRH INITIATIVES FOR AGING IN PLACE NIH Aging in Place Workshop September 10-11, 2014 Presented by Mary Brady, MSN, RN Senior Policy Advisor Center for.
Introduction to the Clinical Laboratory
Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.
Who makes up all these rules?? A discussion on Regulatory Agencies and how they relate to each other and our lab.
1 Serious Adverse Events Following Falsely Elevated Glucose Measurements Resulting from Administration of an IGIV Product Containing Maltose BPAC Meeting,
Proposed Studies to Support the Approval of Over-the-Counter (OTC) Home-Use HIV Test Kits Blood Products Advisory Committee March 10, 2006 Elliot P. Cowan,
Regulatory Decision Making D. Kathleen Wright, Reviewer Division of Microbiology Office of In Vitro Diagnostic Device Evaluation & Safety ( OIVD ) Food.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
TAIEX Workshop on the Accreditation of Medical and Clinical Laboratories (55902) “ROLE AND VALUE OF THE MEDICAL LABORATORIES ACCREDITATION” Aliki Stathopoulou.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Blood Glucose Meter 2010Working Group Report By The Working Group on Medical Measurements The Seventeenth Forum Meeting October 14-16, 2010.
All Hands Electronic Information Integrity Call White Paper An Introduction to the Current State of EMR – et.al. R. L. Chamberlain, Ph.D.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
KEVIN BEDAL LISA CARLIN MATT CARROLL ERIN NICHOLS Product Safety & Failure Analysis.
Point of Care Testing California Clinical Laboratory Association
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Are Laboratory Tests Commodities?
Combination products The paradigm shift
Quality System Considerations for Over-The-Counter HIV Testing
GENERAL PATHOLOGY Diagnostic Services in Health Care that apply to the various diseases The role of diagnostics in Healthcare Quality procedures.
Safety and Regulatory Guidelines In the Medical Laboratory
Quality Control Barbara Weberman MT(ASCP)
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Tobey Clark, Director*, Burlington USA
Point-of-Care vs Laboratory INR Testing to Optimize Anticoagulation Management.
Difficult to prevent reuse of single use devices
Presentation transcript:

1 FDA/CDRH PUBLIC MEETING; Blood Glucose Meters FDA/CDRH PUBLIC MEETING; Blood Glucose Meters FDA Perspective: Regulatory Challenges for Safe use of Blood Glucose Meters in Hospital Settings Carol Benson, M.A., M.T.(ASCP), Associate Director, Division of Chemistry and Toxicology Devices Office of in Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

2 Overview Intended use manufacturers seek FDA clearance Implications under CLIA FDA’s acceptance criteria for accuracy Issues specific to hospital glucose meters/test strips Hospital meters/test strips and post market issues

3 Intended Use Manufacturers of glucose meters/test strips seek FDA clearance for marketing for both: Lay users (OTC) Health care professionals

4 Why seek FDA clearance for both lay user and HP? Glucose monitoring devices cleared by FDA for home use are: CLIA waived device according to regulation

5 Implications of CLIA Waiver Use at any setting with CLIA waiver certificate from CMS Follow manufacturer's instructions for testing and external QC Under CLIA no external QC requirements No PT is required Personnel no training requirements

6 CLIA Waiver Studies¹ More robust than typical lay user studies More samples are tested min. 360 samples More sites used min. at 3 sites Tested over time min. 2 weeks ¹Recommendations: Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices Jan. 30, 2008

7 CLIA Waiver Studies con’t. Accuracy criteria for glucose meters are tighter 95% ± 15% for values ≥ 75 mg/dL, ± 12 mg/dL for < 75 mg/dL Look at other 5% of values Perform flex studies (stress device)

8 Regulatory challenges Same meter/test strips for both lay user & HP many are designed for use by healthcare professionals only and not for lay users Meters are: large, docking stations, bar code capabilities, transmit data, QC lock outs, large memory capacity for storing data

9 Regulatory challenges Same min. accuracy criteria for lay user and health care professional lay users results vs. reference (YSI) method – approx. 100 patients tested health care professionals vs. reference (YSI) 100 patients Same people tested as lay user study – not sick hospitalized patients

10 FDA min. accuracy criteria from the ISO standard Ninety-five percent (95 %) of glucose results are: within ± 15 mg/dL (0,83 mmol/L) of the results < 75 mg/dL (< 4,2 mmol/L) and within ± 20 % of the results ≥ 75 mg/dL (≥ 4,2 mmol/L)

11 Regulator challenges – large differences If 60 mg/dL on reference method then the meter can vary from 45 to 75 mg/dL If 200 mg/dL on reference method then the meter can vary from 160 to 240 mg/dL Only 95% need to meet - if 100 are tested only 95 results meet min. accuracy criteria ?? Other 5 results (5%)

12 ISO min. accuracy criteria Written for meters/test strips for lay users only Should be tightened ?? for lay users Broader than CAP requirements for laboratory based methods – 10% or 6 mg/dL (whichever is greater) Currently FDA applies to all meters/test strips Too broad ? for hospital use meters to be safe and effective

13 Regulatory challenges - other interferences are cumulative Hematocrit Drugs - dopamine, acetaminophen Other substances - lipids, Vitamin C Environmental effects - Temperature – Altitude-Humidity If each affects glucose by 10% and evaluated separately – What is the cumulative effect for patient?

14 Cumulative amount?? Hematocrit +10% Drugs +10% Lipids, Vitamin C +10% Temperature +10% Altitude+10% Humidity +10% ???

15 Hospital patients Sick – dehydrated, in shock, on oxygen Have different hematocrits – not known at time of testing Take multiple drugs – how affect system? May have glucose values changing rapidly Tested with multiple meters/multiple users introduce error – patient treated and …

16 Consequences of hospital patients tested with multiple meters by multiple users? infection control issues (hepatitis) ¹Conclusion: Hepatitis B virus infection outbreaks associated with blood glucose monitoring have occurred with increasing regularity in the Unites States and may represent a growing but under-recognized problem. Advances in technology, such as the development of blood glucose testing meters that can withstand frequent disinfection and noninvasive glucose monitoring methods, will likely prove useful in improving patient safety. ¹J Diabetes Sci Technol 2009;3(2): Nicola D. Thompson, Ph.D., M.S.,1 and Joseph F. Perz, Dr.P.H., M.A.2

17 Hospital patients Insulin dosing errors¹ meters with a 5% total error had <5% of the resulting insulin doses differing from the intended dose at approximately 15% total error large errors in insulin doses, and at 20% total error, >30% of insulin doses differ from intended doses and >16% of episodes of hypoglycemia are missed. 1 - Boyd JC, Bruns DE. Quality specifications for glucose meters: assessment by simulation modeling of errors in insulin dose. Clin Chem 2001;47:

18 Regulatory challenges - hospital patients Intended use – may be different - tight glycemic control – Accuracy needed? Interferences - maltose (either from icodextrine derived or from IgG-containing medication), drugs, oxygen, dehydration, DKA Unawareness of user of potential interferant(s) or limitations

19 Regulatory challenges - hospital meters - labeling Currently same labeling for lay users with added information for health care professionals Same limitations – Not for use on critically ill patients, those in shock, dehydrated Accuracy presented in ISO tables Probably not present with device Not necessarily read by operators Limitations – understood by all users? QC materials – users know when to test?

20 For safe and effective use - Hospital meters Technology improvements Tighter accuracy criteria Less interference from drugs and hematocrit, oxygen, altitude, temperature Less lot to lot variability Lock outs – QC, expired reagents Cleaning procedures to prevent infections

21 Regulatory challenges - Post market signals Glucose meters have one of the highest number of device adverse events reported per year Thousands of Medical Device Reports (MDRs) sent each year (>12,000/yr) 12,672 serious injuries reported from : 100 deaths associated with glucose meters in the MDR database Anyone can report problems From Courtney Harper’s presentation

22 Summary Manufacturers seek FDA clearance for both lay user and Health care professional CLIA waived device FDA currently same min. accuracy criteria from ISO for both lay use and HP Hospital meters used on multiple patients Patients who are critically ill – dehydrated –have different hematocrits – take multiple drugs Infection control issues Post market signals high for glucose meters